Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ucMSC Therapy for Non-viral ACLF
NCT07131306Phase 2Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2027
- Primary completion
- Aug 2031
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in acute-on-chronic liver failure (ACLF) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: 90-day transplant-free survival. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT07131306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131306.